News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Approves Bristol-Myers Squibb Company (BMY)'s Drug That Prevents Organ Rejection


6/16/2011 6:14:28 AM

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY - News) today announced that the U.S. Food & Drug Administration has approved NULOJIX (belatacept).

Please see accompanying Full Prescribing Information, including Boxed WARNINGS at www.NULOJIX.com or www.bms.com.

NULOJIX is a registered trademark of Bristol-Myers Squibb.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES